This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 594| Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
|---|---|---|---|---|---|---|---|---|---|
| 2451 | IPO9 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.64 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2452 | MTA3 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.61 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2453 | CSRP2BP | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.57 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2454 | XPO1 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.44 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2455 | C14orf93 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.43 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2456 | C5orf13 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.56 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2457 | EHMT2 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.80 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2458 | STX6 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.24 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2459 | MCM8 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.34 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2460 | MEF2B | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.49) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2461 | FAM34A, NARS, HSPC152, GRP58, GBA, PVRL2, RPS17, LAMR1, GNB1, AHNAK, GRCC10, SPTAN1, CTSC, NSE1, COP1, NDRG1, HSPA5, SPARC, ATP5J2, KIAA0663, CD24, NUDT3, CANX | RNAs | Human | Downregulated in among all types HCC v/s non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 16391793 |
| 2462 | SMYD3, FABP1, Ceruloplasmin, A2M, IGFBP, PPAP2B, SHMT, PHLDA1, APOA1, SOCS2, ETS2, MT2A, CYP39A1, HAMP, CYP2C9, SLC22A1, PLG, GAMT, FGG, KRT8, IFITM1, C1R, FGB, FGA, GC (vitamin D binding protein), SERPINA3, WAC, | RNAs | Human | Upregulated in among all types HCC v/s non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 16391793 |
| 2463 | CLU | RNAs | Human | Upregulated in metastatic HCC than primary HCC | Diagnostic and Prognostic | Primary and metastatic HCC | p < 0.001 | Cell line and Tissue | 16247463 |
| 2464 | EGR3, MFAP3, EST, MMP9, PDCD4, EST, FLJ37853, ARHE, MAD2L1, NMNAT2, FLJ22016, SND1, MIDORI, FLJ36229, MGST2, CTPS2, OASL, HK2, EEF2, Taxilin, NT5C, CLNS1A, UNC5B, TSC, TNFSF6, KIAA1691, S100A10, ATP6V1D, ASB4, AGR2, KIAA0205, JJAZ1, LOC285859, KIAA0157, PPA2, eIF3k, SGKL, BLMH, ERG-1, BRCA2, PPP2R2A | RNAs | Human | Differentially expressed (14 Upregulated and 49 Downregulated) in treatment responder v/s non-responders | Predictive | treatment responder v/s non-responders | p < 0.01 | Tissue | 15447987 |
| 2465 | GPC3, CAP2, UBD, MT1F, PTDSS1, RDS, ID1, NNMT, AA127809, PRRG2, ACAA1, SLC22A1, BE779749, FACL2, PRLR, C8orf4, C6, CCNH, AK022114, CBFA2T3, EPAS1, API5, SULT2A1, PGM1, C9, NQO1, C1R, PMS1, DSCR1, PPP1R2, GOT1, ZNF6, AI831040, GCLC, MYOZ2, HMGCL, UBE4A, SERPING1, PLG, ADFP, RODH, MARCO, C9orf59, BG71 | RNAs | Human | Differentially expressed (GPC3, CAP2, UBD Upregulated and rest 41 are Downregulated) in tumor v/s non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.001 | Tissue | 15607117 |
| 2466 | MT1B, MT1E, MT1L, CP, ABCA1, CACNB3, PROS1, CPB2, SERPINC1, LACI, MDK, C6, C9, CD5L, GPR126, IL1RAP, DYRK3, PCDH17, TACSTD1, UAP1, C20orf3, CFL2, FLJ12666, KIAA0843, MRC1, NAT2, MYO1B, SIPL, SRD5A2, USP1, | RNAs | Human | Differentially expressed (PCDH17, MDK, TACSTD1 Upregulated and rest 27 are Downregulated) in High-risk individuals with cirrhosis v/s patients with HCC | Prognostic | High-risk individuals with cirrhosis v/s patients with HCC | p < 0.0003 | Tissue | 14768006 |
| 2467 | GRP94, GRP78, GRP75, HSC71, HSP90, HSP70, HSP60, Aconitase, EF-2, Nucleophosmin, VIM, NDK-A, Argininosuccinate synthase, CPSASE-I, | Protein | Human | Differentially expressed (Argininosuccinate synthase, Carbamoyl-phosphate synthase (CPSASE I) are Downregulated and rest 12 are Upregulated) in HCC tumor v/s non-tumorous | Diagnostic | HCC tumor v/s non-tumorous | p < 0.05 | Tissue | 14654528 |
| 2468 | hnRNP K, HSP70RY, Lamin B1, 40S ribosomal protein SA, FTCD, SOD, Arginase, SMP-30, P5C dehydrogenase, Transitional endoplasmic reticulum ATPase, Ubiquitin carboxyl-terminal hydrolase 5, Thiosulfate sulfurtransferase (Rhodanese), Betaine-himocysteine S-methyltransferase, NCC27, FGB, RACK1, PDI, SARDH | Protein | Human | Differentially expressed (hnRNP K, HSP70 RY, Lamin B1, 40S ribosomal protein SA, Transitional endoplasmic reticulum ATPase, Ubiquitin carboxyl-terminal hydrolase 5, Rhodanese, Betaine-himocysteine S-methyltransferase, NCC27, Fibrinogen β chain, RACK1 are Upregulated and rest 12 are Downregulated) | Diagnostic | HBV associated HCC tumor v/s non-tumorous | p < 0.05 | Tissue | 14654528 |
| 2469 | GABA-AT, Cytosol aminopepsidase, AFB1-AR2, Acyl-CoA dehydrogenase, GDH, | Protein | Human | Differentially expressed (GABA-AT, AFB1-AR2) are Upregulated and rest 3 are Downregulated) in HCC tumor v/s non-tumorous | Diagnostic | HCV associated HCC tumor v/s non-tumorous | p < 0.05 | Tissue | 14654528 |
| 2470 | HSP27, Enoyl-CoA hydratase, Tubulin β chain, Galactose kinase, Ubiquinol-cytochrome C reductase complex core protein I, Annexin V, P-PST, Ribosome binding protein, Fumarylacetoacetase, ALDH, Catalase, | Protein | Human | Differentially expressed (P-PST, Ribosome binding protein, Fumarylacetoacetase, Catalase and ALDH are Downregulated and rest 6 are Upregulated) in HCC tumor v/s non-tumorous | Diagnostic | Both HBV- and HCV associated HCC tumor v/s non-tumorous | p < 0.05 | Tissue | 14654528 |
| 2471 | Protein disulfide isomerase ER-60, PRBP, Tropomyosin 3, ATP synthase, Dihydropipoamide dehydrogenase, FABP, Cathepsin B1, | Protein | Human | Differentially expressed (FABP, Cathepsin B1 are Downregulated and rest 5 are Upregulated) in HCC tumor v/s non-tumorous | Diagnostic | both (HBV and HCV) negative HCC tumor v/s non-tumorous | p < 0.05 | Tissue | 14654528 |
| 2472 | AURKB | Protein and RNAs | Human | Upregulated in HCC tissues in association with aggressive recurrence v/s non-recurrence | Prognostic | Aggressive recurrence HCC v/s non-recurrence HCC | p < 0.001 | Tissue | 18311747 |
| 2473 | hnRNP C1/C2 | Protein | Human | Upregulated in HCC tissues in HCC tumor than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 17627933 |
| 2474 | Hcp70/Hsp90-organizing protein (HOP) | Protein | Human | Upregulated in HCC tissues in HCC tumor than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 17627933 |
| 2475 | GRP-78 | Protein | Human | Upregulated in HCC tissues in HCC tumor than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 17627933 |
| 2476 | heat shock 70-kDa protein 1 | Protein | Human | Upregulated in HCC tissues in HCC tumor than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 17627933 |
| 2477 | heat shock 70-kDa protein 4 | Protein | Human | Upregulated in HCC tissues in HCC tumor than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 17627933 |
| 2478 | T-complex protein 1 | Protein | Human | Upregulated in HCC tissues in HCC tumor than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 17627933 |
| 2479 | MAT | Protein | Human | Downregulated in HCC tissues in HCC tumor than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 17627933 |
| 2480 | GNMT | Protein | Human | Downregulated in HCC tissues in HCC tumor than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 17627933 |
| 2481 | BHMT | Protein | Human | Downregulated in HCC tissues in HCC tumor than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 17627933 |
| 2482 | COMT | Protein | Human | Downregulated in HCC tissues in HCC tumor than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 17627933 |
| 2483 | MYO1D, EST, PDGF-B, LOC113246, SPTAN1, MGC19556, IL6R, PRPSAP1, PDCD6IP, AHNAK, BCL2L11, GPAA1, c-fos, SLC11A2, LOC51235, PRPF8, CD36L1, KIAA1055, HNRPDL, NDRG1, NARS, PABPC4, RDBP, CALM2, PDCD6, C1R, ALB, MT1G, CED-6, AMACR, A2M, FGG, SUPV3L1, PHLDA1, NBP, HAMP, HCS, KIAA0635, ECHS1, SHMT1, NNMT, A | RNAs | Human | Differentially expressed between HCC and non-tumor liver tissue | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 14642619 |
| 2484 | SOX6, ITIH4, HDGF, SKIP1, RBP4, LOC92033, UGT2B7, FABP1, GATM, UQCRC1, UK114, CP, PBEF, KAL1, CES2, GPX4, UGT1A4, RCL, PABPC1, EST, FGA, RARRES2, SLC22A, SRP14, FLJ14294, cyclin, CA2, CLDN1, FTL, FLJ10004, CYP3A5, ARHGEF12, TDO2, NDUFB2, TEGT, SPR, PCK2, MGC13114, EST, MTHFS, F2, FLJ22313, C9orf5, H | RNAs | Human | Differentially expressed between HCC and normal tissues | Diagnostic | HCC v/s normal | p < 0.01 | Tissue | 14642619 |
| 2485 | IGFBP3, c-fos, p21 | RNAs | Human | Differentially expressed between HCC and non-tumor liver tissue | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 14642619 |
| 2486 | p53, cyclin D1 | RNAs | Human | Differentially expressed between HCC and normal tissues | Diagnostic | HCC v/s normal | p < 0.01 | Tissue | 14642619 |
| 2487 | Protein disulfide isomerase A3 | Protein | Human | Upregulated in HCC than non tumor (with mean ratio of 4.3 +/- 3.7) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 12481271 |
| 2488 | Heat shock 27 kDa protein | Protein | Human | Downregulated in HCC than non tumor (with mean ratio of nearly 8.4 +/- 5.8) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 12481271 |
| 2489 | Glycerol-3-phosphate dehydrogenase | Protein | Human | Downregulated in HCC than non tumor (with mean ratio of nearly 9.9 +/- 9.6) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 12481271 |
| 2490 | Senescence marker protein-30 | Protein | Human | Downregulated in HCC than non tumor (with mean ratio of nearly 7.9 +/- 11.1) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 12481271 |
| 2491 | Acyl-CoA dehydrogenase | Protein | Human | Downregulated in HCC than non tumor (with mean ratio of nearly 4.7 +/- 2.5) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 12481271 |
| 2492 | Ketohexokinase | Protein | Human | Downregulated in HCC than non tumor (with mean ratio of nearly 4.7 +/- 3.7) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 12481271 |
| 2493 | GRB2 | Protein | Human | Downregulated in HCC than non tumor (with mean ratio of nearly 6.7 +/- 5.4) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 12481271 |
| 2494 | Aldehyde dehydrogenase | Protein | Human | Downregulated in HCC than non tumor (with mean ratio of nearly 3.7 +/- 2.8) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 12481271 |
| 2495 | Cathepsin D | Protein | Human | Downregulated in HCC than non tumor (with mean ratio of nearly 3.5 +/- 3.3) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 12481271 |
| 2496 | Guanidinoacetate N-methyltransferase | Protein | Human | Downregulated in HCC than non tumor (with mean ratio of nearly 5.3 +/- 8.6) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 12481271 |
| 2497 | Catechol O-methyltransferase | Protein | Human | Downregulated in HCC than non tumor (with mean ratio of nearly 3.2 +/- 3.8) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 12481271 |
| 2498 | TGM2 | Protein | Human | Upregulated in HCC than non tumor | Diagnostic | HCC v/s normal | p < 0.05 | Cell line, Tissue, Serum | 18646787 |
| 2499 | SEMA3F, DDX17, TNFAIP, PDGFRA, VIM, LAPTM5, CCND2, HLADRA, MEF2C, Staf50, SGK, REL, | RNAs | Human | Diffrenetially Expressed between recurrent and non-recurrent HCC | Prognostic | Early intrahepatic recurrence and non-recurrence HCC | p < 0.05 | Tissue | 12648972 |
| 2500 | RYBP, ATP1B3, TMC, ZNF567, GPR108, CD19, SPINK1, CDC2L6, RSRC1, METAP, GPC3, SNHG11, RY1, CRELD2, GLUL, SERPINB1, TRMT6, UNC13D, E4F1--E4F, SLC22A2, CNIH4, TK1, MAFB, PPP1CB, DNTTIP2, ARID4B, SMARCC2, PRO1386, TRIOBP, VARS, ITGA5, TERF1, PURA, TUBA1B, SNRPE, RRAGD, VWF, GLRX3, ILF2, | RNAs | Human | Upregulated in HCV related HCC than normal control (With 3-fold change) | Diagnostic | HCV related HCC v/s normal control | p < 0.01 | Tissue | 19821982 |